Bruno Bastos Application PackageBastos Bruno
Last Name First Name Middle Initial
1501 W 21St St Miami Beach
Home Address City
FL 33140
State Zip Code
78645328847865962000
HomeWork
Brunobmd@icloud.com
Email Address
6173206498
Cellular
Business Address City State Zip Code
Occupation:Business Name:
Please list your preferences in order of ranking [1] first choice [2] second choice, and [3] third choice. Please note
that only three (3) choices will be observed by the City Clerk’s Office. (Regular Boards of City)
Choice 1:
Choice 2:
Choice 3:
Health Advisory Committee
Health Facilities Authority Board
Parks and Recreational Facilities Board
BOARD AND COMMITTEE
APPLICATION FORM
Note:If applying for the At-Large position of the Historic Preservation Board, please answer the below
questions:
Have you ever resided in one of the City's Historic Districts for at least one year?No
No Address in City Historic District submitted.
Professional License
License Number Issuance Date Expire Date
Florida Department of Health
Licensed Health Care ME105209 7/27/2009 1/31/2025
Note:If you are seeking appointment to a professional seat (e.g. attorney, architect, etc.), you must attach a copy of
your currently effective corresponding professional license.
Pursuant to City Code section 2-22(4) a, b and c: Members of Agencies, Boards, and Committees shall be
affiliated with the city. This requirement shall be fulfilled in the following ways:
YesResident of the City for a minimum of six (6) months:
Demonstrate an ownership interest in a business established in the City for a minimum of six (6) months:No
AFFILIATION WITH THE CITY OF MIAMI BEACH
a.
● I am resident of:South Beach
Or
b.
"Ownership Interest" shall mean the ownership of ten percent (10%) or more (including the ownership of 10%
or more of the outstanding capital stock) in a business.
"Business" shall mean any sole proprietorship, sponsorship, corporation, limited liability company, or other
entity or business association.
c.Full-time employee of such a business (for a minimum of six months); and I am based in an office or
other location of the business that is physically located in Miami Beach (for a minimum of six months):No
Notwithstanding the requirements set forth herein, the qualified full-time employee of a business must be
approved by a 4/7th vote of the Mayor and City Commission.
NOTE: Members of Agencies, Boards, and Committees shall be required to demonstrate compliance with the City
affiliation requirements of section 2-22 (4) a and b of the Miami Beach City Code by executing an affidavit,
stipulating that they have met either (or both) of said affiliation requirements. The original affidavit shall be filled
with the Office of the City Clerk prior to being sworn in as a member.
Or
No● Have you ever been convicted of a felony:If yes, please explain in detail:
● Do you currently have a violation(s) of City of Miami Beach codes:No If yes, please explain in detail:
● Do you currently owe the City of Miami Beach any money:No If yes, please explain in detail:
● Are you currently serving on any City Boards or Committees:No If yes, which board?
● Are you presently a registered lobbyist with the City of Miami Beach?No
● I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
NOTE: IF APPOINTED, YOU WILL BE REQUIRED TO FOLLOW CERTAIN LAWS THAT APPLY TO CITY
BOARD/COMMITTEE MEMBERS. THESE LAWS INCLUDE, BUT ARE NOT LIMITED TO:
o Prohibition from directly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).
o Prohibition from contracting with the city (Miami-Dade County Code section 2-11.1).
o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office
(Miami Beach Code section 2-26)
o Requirement to disclose certain financial interests and gifts (Miami-Dade County Code section 2-11.1).
o Sunshine Law - Florida's Government-in-the-Sunshine Law was enacted in 1967. Today, the Sunshine Law
regarding open government can be found in Chapter 286 of the Florida Statutes. These statutes establish a basic
right of access to most meetings of Boards, Commissions, and other governing bodies of state and local
governmental agencies or authorities.
o Voting conflict - Form 8B is for use by any person serving at the county, city, or other local level of government on
an appointed or elected Board, Council, Commission, Authority, or Committee. It applies equality to members of
advisory and non-advisory bodies who are presented with a voting conflict of interest under Section 112.3143.
Florida Statutes.
● In what organization(s) in the City of Miami Beach do you currently hold membership in?
No Organization Information Submitted.
● List the address of all properties owned or in which you have an interest within the City of Miami Beach:
No Owned Property Information submitted.
If so, which department and title?No● Are you now employed by the City of Miami Beach:
● Pursuant to City Code Section 2-25 (b):
Do you have a parent, spouse, child, brother, or sister who is employed by the City of Miami Beach?No
If "Yes", identify person(s) and department(s):
No relative's information submitted.
BOARD & COMMITTEE FINANCIAL ACKNOWLEDGEMENT STATEMENT
Acknowledgement of fines/suspension for Board/Committee Members for failure to comply with
Miami-Dade County Financial Disclosure Code Section 2-11.1(i)(2)
I understand that no later than July 1, of each year all members of Boards and Committees of the City of Miami
Beach, including those of a purely advisory nature, are required to comply with Miami-Dade County Financial
Disclosure Requirements.
One of the following forms must be filled with the City Clerk of Miami Beach, 1700 Convention Center Drive,
Miami Beach, Florida, no later than 12:00 noon of July 1, of each year:
1. A "Source of Income Statement;" or
2. A "Statement of Financial Interests (Form 1)¹ ;" or
3. A Copy of your latest Federal Income Tax Return.
Failure to file one of these forms, pursuant to the Miami-Dade County Code, may subject the person to a fine of no
more than $500, 60 days in jail, or both.
_____________________________
¹ Members of the Planning Board and Board of Adjustment will be notified directly by the State of Florida, pursuant
to F.S. §112.3145(1)(a), to file a Statement of Financial Interests (Form 1) with the Miami-Dade County Supervisor of
Elections by 12:00 noon, July 1. Planning Board and Board of Adjustment members who file their Form 1 with the
County Supervisor of Elections automatically satisfy the County’s financial disclosure requirement as a Miami Beach
City Board/Committee member and need not file an additional form with the Office of the City Clerk. However,
compliance with the County disclosure requirement does not satisfy the State requirement.
DIVERSITY STATISTICS REPORT
The following information is voluntary and has no bearing on your consideration for appointment. It is being asked to
comply with City diversity reporting requirements.
WhiteRace/Ethnic Categories
What is your race?
No details providedOther Description:
Gender:Male
Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino.Yes
Physically Challenged:No
UNDER PENALTIES OF PERJURY, I DECLARE THAT I HAVE READ THE FOREGOING APPLICATION AND
THAT THE FACTS STATED IN IT ARE TRUE. ADDITIONALLY, I AGREE AND ACKNOWLEDGE THAT ANY
FALSE STATEMENTS OR FALSE INFORMATION SUBMITTED AS PART OF THIS APPLICATION SHALL BE
A BASIS FOR MY REMOVAL FROM A CITY BOARD OR COMMITTEE. I HAVE RECEIVED, READ, AND WILL
ABIDE BY CHAPTER 2, ARTICLE VII, OF THE MIAMI BEACH CITY CODE, ENTITLED “STANDARDS OF
CONDUCT FOR CITY OFFICERS, EMPLOYEES AND AGENCY MEMBERS” AND ALL OTHER APPLICABLE
CITY, COUNTY, AND/OR STATE LAWS AND STATUTES ACCORDINGLY.
I Bruno Bastos agreed to the following terms on 2/8/2023 4:13:09 PM
Received in the City Clerk's Office by:
Name of Deputy Clerk Control No. Date
Board and Committee Application Checklist: Please ensure you have provided all information before applying or
reapplying to any Board and Committee.
YES
YES
YES
YES
I have answered all questions fully.
I have uploaded a current resume, photograph, and a copy of any applicable professional license.
I have completed and attached the Board & Committee Financial Acknowledgment Statement.
I have completed and attached the Diversity Statistics Report.
If you have any questions, please contact the Office of the City Clerk via email: BC@miamibeachfl.gov or
telephone: 305.673.7411
Note: Florida Statutes 119.071: The role of the Office of the City Clerk is to receive and maintain forms filed as
public records. If your home address, telephone numbers, and/or photograph are exempt from disclosure and you
do not wish your home address, telephone numbers, and/or photograph to be made public, please:
1) Use your office or other address for your mailing address;
2) Use your office or other telephone number for your contact number; and
3) Do not attach a photograph.
CURRICULUM VITAE
General Information
Name: Bruno Rossi Bastos
Home Address: 1501 W 21st Street, Miami Beach FL 33140
Office Address: Miami Cancer Institute, 8900 N Kendall Dr, Suite 2N429, Miami, FL
33176
Work Phone: (786) 596-2000
Cell Phone: 617.320.6498
E-mail: brunoba@baptisthealth.net
Place of Birth: Brazil
Citizenship: US, Brazil, Italy
Languages: English, Spanish, Portuguese (Native)
Medical Degree Education:
03/1995-12/2001:
M.D., Universidade Federal da Bahia
ECFMG Certification:
May 1, 2002 Certificate number 0-639-284-1
Postdoctoral Training:
07/2008-09/2009:
Special Clinical Fellow, Developmental Therapeutics
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School. Boston, MA
07/2005-06/2008:
Clinical Fellow, Hematology/Oncology
Department of Medicine (Hematology/Oncology dept), University of Miami. Miami, FL
06/2002-06/2005:
Resident Internal Medicine
Department of Medicine, University of Miami, Miami, FL
01/2002-06/2002: Application process for US residency.
State of Florida Appointment:
2015-19: Appointed by Governor of Florida to the Florida Center for Brain Tumor
Research Scientific Advisory Council
Clinical Appointments
May 2019-Present:
Hematologist/Oncologist (Focus in Genito-urinary
Malignancies/Phase 1 Clinial Trials.)
Miami Cancer Institute/Baptist Health Medical Group Oncology,
Baptist Medical Hospital, South Miami Hospital, West Kendall
Baptist Hospital, Homestead Baptist Hospital, Mariners Hospital.
October 2009- May 2019:
Hematologist- Oncologist. Staff
Department of Hematology/Oncology, Cleveland Clinic FL. Weston, FL.
December 2008- October 2009:
Physician/Moonlighter
Internal Medicine. Brigham and Women’s Hospital. Boston, MA.
Academic Appointments:
2015-19: Clinical Assistant Professor of Medicine. Case Western Reserve
University – School of Medicine
2013-19: Program Director of the Cancer Research Fellowship Program at
Cleveland Clinic Florida
2010-: Clinical Assistant Professor, Department of Medicine, Florida
International University, Herbert Wertheim College of Medicine
2010-: Affiliate Assistant Professor, Charles E. Schmidt College of Medicine,
Florida Atlantic University
Hospital or Affiliated Institution Leadership Appointments:
2022: Member. Physician Grateful Advisory Council. Baptist Health Foundation
2022: Ambassador. Baptist Health Foundation.
2022: Group Leader. John Hopkins University School of Medicine. Gather-ed
platform/Medical Logix.
2022: Advisor. Sanofi GU Oncology. Board of Advisors.
2020: Committee Member. Research Steering Committee. Miami Cancer
Institute
2019: Committee Member. CSRC. Miami Cancer Institute
2019: Lead Physician, Multiple Tumors/Phase I clinic. Miami Cancer Institute
2019: Site Research Leader, US ONCOLOGY at MCI
2019: Committee Member, ECOG-ACRIN GU Early Modality Committee.
2019: Member. MSK-EDD Alliance Early Phase Clinical Trials.
2018-19: Committee Member Physician Engagement. CCF
2017: Mentor ASCO Diversity Mentorship Program
2017: Committee Member FLASCO Cancer Disparities
2017: Volunteer ASCO Volunteer Corps
2016: Committee Member Education Committee- International Association for
the Study of Lung Cancer IASLC
2016: Committee Member Communications Committee - International
Association for the Study of Lung Cancer IASLC
2015-19: Committee Member of the Global Patient Services (GPS) Advisory
Council, Cleveland Clinic Florida
2013: Committee Member, Prostate Cancer Advisory Board, FPCR
2012: Committee Member, Developmental Therapeutics, the Alliance for
Clinical Trials in Oncology
2011-19: Medical Director of Cancer Research, Department of Hematology
Oncology, Cleveland Clinic Florida
2011-19: Program Director, Visiting Researcher Fellowship in Oncology
2011-19: Responsible Investigator, Cleveland Clinic Florida, NIH-sponsored
Community Clinical Oncology Program (CCOP) Clinical Trials
2010-19: Co-Director of the Lung Cancer Center, Cleveland Clinic Florida
2010: Director of the Oncology Tumor Board, Cleveland Clinic Florida
2010-19: Committee Member of the Pharmacy & Therapeutics Committee,
Cleveland Clinic Florida
2009: Editorial Board Team of the Journal of Thoracic Disease
Professional Societies (Membership):
2020: European Society of Medical Oncology (ESMO)
2018: Society for Neuro-Oncology (SNO)
2018: ACCRU, Academic and Community Cancer Research United
2014: SWOG
2014: Florida Society of Clinical Oncology (FLASCO)
2011: Cancer Trials Support Unit (CTSU)
2010: International Association for the Study of Lung Cancer (IASLC)
2010: Alliance
2010: ECOG-ACRIN
2009: CTEP/NIH
2008: Massachusetts Medical Society
2009: American Association for Cancer Research (AACR)
2006: American Society of Clinical Oncology (ASCO)
2006: American Society of Hematology (ASH)
2003: American College of Physicians (ACP)
2002: American Medical Association (AMA)
Awards and Honors:
2022: Author!Author!Day. National Library Week. Miami Cancer Institute.
Honored Staff Author
2021: Author!Author!Day. National Library Week. Miami Cancer Institute.
Honored Staff Author
2018: Award of Excellence in Research & Academic Achievement. Maroone
Cancer Center 2017
2016: First Prize. Poster Competition at the Florida Bladder Cancer Symposium
2016: Appreciation Award, Caregiver Celebration-Cleveland Clinic. Core Value:
Compassion
2013: Caregiver Hero-Cleveland Clinic Florida
2009: ASCO/AACR Workshop Methods in Clinical Cancer Research
Scholarship
2006: AMGEN Young Investigator Forum Award
2006: National Lung Cancer Partnership Travel Award
2003: Internal Medicine Residency Annual Case Presentation Competition,
University of Miami
2003: Student Inpatient Teaching Award, School of Medicine, University of
Miami
2000: CICAN- State of Bahia Cancer Center Scholarship
2000: PIBIC/CNPq-Brazilian Scholarship for Graduate Research
Special Externship:
2005: NIH/NCI - Clinical Rotation in Hematology
Ad Hoc Reviewer:
2021: FLASCO - Oncology Fellow & Resident Educational Training Program.
Abstract Reviewer. March 19, 2022.
2018: JCO Precision Oncology
2017: Journal of Community and Supportive Oncology
2017: HPB
2016: JAMA Oncology
2016: Frontiers in Oncology
2016: Journals of the American College of Clinical Pharmacy
2013: Drug Design, Development and Therapy
2013: Lung Cancer: Targets and Therapy
2013: Onco-Targets and Therapy
2013: Pharmacogenomics and Personalized Medicine.
2013: Frontiers in Thoracic Oncology
2013: American Journal of Clinical Oncology
2013: Oral Oncology
2012: Pharmacotherapy
Poster Judge Competition:
2014-2016: Cleveland Clinic Florida - Resident and Fellow Research Week. Poster
Judge. Weston- FL
2013: Florida Chapter Meeting/American College of Physicians. Poster Judge
TEACHING
a. International Presentations:
2021: Update in targeted therapies in lung cancer (RET, ROS1, NTRK and
KRAS G12C). Brasilia, Brazil. December 2021. Invited Speaker
2021: Update in targeted therapies in lung cancer (RET, ROS1, NTRK and
KRAS G12C). VIII Simposio Internacional de Cancer de Pulmao. Sao
Paulo. March 6th, 2021. Invited Speaker.
2020: Targeted therapies and Immunotherapy in Lung Cancer: COVID-19
impact. Online live round-table conference. April 29, 2020. Sao Paulo,
Brazil www.pcomunic.com.br/onconnection. Invited Speaker
2019: Immunotherapy in mutation driven tumors: when to offer? VII Simposio
Internacional de Cancer de Pulmao. March 15-2019. Sao Paulo, Brazil.
Invited Speaker
2019: Update 2019 in the management of targeted therapies (BRAF, MET, RET,
ROS1, HER2). VII Simposio Internacional de Cancer de Pulmao. March
15-15, 2019. Sao Paulo. Brazil. Invited Speaker.
2019: Immunotherapy versus Cytotoxic in the Therapy of Cancer. Medical
Association of the Bahamas scientific Conference. March 13-15, 2019.
Nassau, Bahamas. Invited Speaker.
2017: Novel immunotherapeutic combinations in Lung Cancer. 55th Annual
Meeting of JSCO. October 20-22, 2017. Yokohama, Japan. Invited
speaker
2017: Update in Head and Neck Cancer. Best of ASCO 2017 Panama. Panama
City, Panama. Invited Speaker.
2016: Update in Head and Neck and CNS malignancies. Best of ASCO 2016.
Panama City, Panama. Invited Speaker
2014: Moving to Personalized Medicine in Lung Cancer Diagnosis and Therapy.
IASLC/ESMO Session Chair. LALCA 2014. Lima, Peru. Invited
Moderator
2014: Therapy of EGFR/ALK Resistant Lung Cancer. LALCA 2014, Lima,
Peru. Secretary. Round Table #10. Invited Moderator
b. Invited National/Regional Presentations:
2022: Improving the Care of Patients with Advanced and Metastatic Renal Cell
Carcinoma through a Digital Inter-professional Social Learning Platform.
Johns Hopkins University School of Medicine. CME/CE event. Gather-ed
platform/Medical Logic. Group Leader.
2022: Best of ESMO 2022. Treatment of Oligo-metastatic Prostate Cancer. Fort
Lauderdale. Speaker
2022: Targeted Oncology. Virtual Case-based Roundtable Meeting on Prostate
Cancer. Moderator. August 31, 2022. Co-moderator
2022: ASCO Direct. Prostate Cancer. Best of ASCO Review, Philadelphia, FL
Speaker
2022: ASCO Direct. Prostate Cancer. Best of ASCO Review. Jacksonville, FL
Speaker
2022: OncLive State of the Science Summit. Genitourinary Cancer. Miami-FL.
May 18th 2022. Program Chair/Ambassador.
2022: OncLive State of the Science Summit. Frontline Treatment of mRCC
(CABOSUN, CheckMate 9ER, CheckMate 214, CLEAR) Speaker.
Genitourinary Cancer. Miami-FL. May 18th 2022. Speaker
2022: OncLive State of the Science Summit. Second and Later Line Treatment
of mRCC/TIVO-3) Speaker. Genitourinary Cancer. Miami-FL. May 18th
2022. Speaker
2022: MCI-Grand Rounds. Targeting Cancer Cell Metabolism. May 9th, 2022.
Speaker
2021: MSK Experimental Drug Development (EDD) Phase I Meeting. Virtual.
Speaker.
2021: Prostate Cancer: Sequencing for Metastatic Castration Resistant. Targeted
Therapies. Case-Based Round Table Meeting. Webinar. August 18th,
2021. Co-moderator
2021: Oncology I. Cleveland Clinic Florida Internal Medicine Board Review.
Speaker. July 2021
2021: Grand Rounds Family Medicine Residency. Oncology - Board Review.
Borinquen Residency Program. May 2021. Spaker
2020: Oncology I. Cleveland Clinic Florida Internal Medicine Board Review.
Speaker. July 2020
2020: ASCO virtual Direct Highlights. Genitourinary Cancer – Prostate Cancer.
Jacksonville FL. Total Health Conferencing. July 2020. Speaker.
2019: ESMO 2019 – GU Oncology Highlights. Total Health Conference.
November 16, 2019. Fort Lauderdale, Florida. Speaker
2019: Oncology I. Cleveland Clinic Florida Internal Medicine Board Review.
Speaker
2019: Targeted Therapies and Side Effects. 9th Annual Winter Oncology
Symposium. March 1-2, 2019. Fort Lauderdale. Speaker
2019: Emerging Role of Immunotherapy in Head and Neck Cancer. 2019
Multidisciplinary Head and Neck Cancer. Fort Lauderdale FL. Speaker
2018: Oncology I. Cleveland Clinic Florida Internal Medicine Board Review.
Speaker
2018: Emerging Role of Immunotherapy in Head and Neck Cancer. 2018
Multidisciplinary Head and Neck Cancer. Key Largo FL. Speaker
2018: Round table. Case discussion Skin and Thyroid Cancer cases .
Multidisciplinary Head and Neck Cancer. Key Largo FL. Panelist
2018: Round table. Case discussion Head & Neck Cancer-Immunotherapy.
Multidisciplinary Head and Neck Cancer. Key Largo FL. Panelist
2018: Targeted Therapies for Metastatic Disease. Tampa Florida. Bladder
Cancer Update. CME-event. Speaker
2018: Brain Tumor Summit. University of Florida. Tallahassee FL. Scientific
Advisor Board Member.
2018: First GU Oncology Symposium. Cleveland Clinic Florida January 2018.
Challenge the Professor GU Oncology clinical cases. January 2018.
Weston-FL. Speaker and meeting organizer
2017: Consequences of the Increasing Use of Immunomodulators to Treat
Patients with Cancer. Medical Grand Rounds. Cleveland Clinic Florida.
August 23rd, 2017. Speaker
2017: Update in Bladder Cancer. Target Therapies for Metastatic Disease. Hard
Rock Café, Fort Lauderdale, FL. August 22, 2017. Speaker
2016: Update in Lung Cancer. Medical Grand Rounds. Larkin Internal Medicine
Program. Miami-FL. Speaker
2016: Using Precision Medicine in the neo-Adjuvant Treatment for the treatment
of Muscle-Invasive Bladder Cancer (MIBC). Florida Bladder Cancer
Symposium. November 2016. Speaker
2016: Immunotherapy in Head and Neck Cancer. 2016 Multidisciplinary Head
and Neck Cancer. Fort Lauderdale-FL. Speaker
2014: Clinical Trials and Novel Agents in Advanced Prostate Cancer. Potential
for Inter-Institutional Collaboration. Third Annual Florida Prostate Cancer
Research Symposium. Session Moderator
2013: Clinical Trials and Novel Agents in Advanced Prostate Cancer. P otential
for Inter-Institutional Collaboration. Second Annual Florida Prostate
Cancer Research Symposium. Speaker
2013: Chemotherapy in Low Grade Gliomas; First Annual International Brain
Tumor & Spine Surgery Symposium, Jagelman Conference Center,
Cleveland Clinic, Weston FL. Speaker
2012: Chemotherapy in metastatic brain tumors; First Annual International Brain
Tumor & Spine Surgery Symposium, Jagelman Conference Center,
Cleveland Clinic, Weston FL. Speaker
2012: Chemotherapy in Low Grade Gliomas; First Annual International Brain
Tumor & Spine Surgery Symposium, Jagelman Conference Center,
Cleveland Clinic, Weston FL. Speaker.
2011: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitors; 2011
Florida Brain Tumor Biomedical Technology Summit on May 14, 2011 at
the Peabody Hotel in Orlando, FL. Speaker.
2008: Consolidation Docetaxel After Concurrent Chemoradiotherapy with
Carboplatin and Irinotecan in Unresectable Stage III NSCLC,; Boston
Medical Center, Boston, MA. Speaker.
2006: Overcoming Cisplatin Resistance with mTOR Inhibition; 10th Annual
Joint Cancer Conference of the Florida Universities, Orlando FL. Speaker.
2004: Complete Remission of Oral Plasmablastic Lymphoma with Antiviral
Therapy; 8th Annual Joint Cancer Conference of the Florida Universities,
Orlando FL. Speaker.
2003: A Man Presenting with Tooth Pain; Clinical Case Presentation, American
College of Physicians, St. Petersburg, FL. Speaker.
c. Community Outreach/Philanthropic Activities
2022: Invited Speaker, Fund Raiser and Organizer. Swim
Across America – Open Swim Fund raising Event. Islamorada, FL
2021: Invited Guest. Heat-Help-/cure 2022 Launch Event. Miami-FL
2017: Speaker. Bonnie Adadrio Round Table Series in Lung Cancer.
2011: Moderator. Cleveland Clinic Online Health Chats. Lung Cancer.
2010: Moderator. Man to Man Group – Monthly Prostate Cancer Support Group
Meeting.
d. Mentorship:
2017: Mentorship-ASCO Diversity Mentoring
2016: Mentorship–ASCO/JSCO
2011-2016: Mentorship. The Weber Family Summer Scholar Program.
d. Clinical Teaching
2018- Monthly Research Oversight Meeting. MCI.Organizer/Presenter
2018- Bi-weekly MCI Tumor Board (GU) Speaker
2008- Bi-weekly Cleveland Clinic Tumor Board (GU/Neuro Oncology/Thoracic
Oncology/Head & Neck). Speaker
2008- Internal Medicine Residency Program – Cleveland Clinic Florida.
Faculty/Attending.
2008- Geriatrics Fellowship Program – Cleveland Clinic Florida.
Faculty/Attending.
e. Media Publications
2022: Youtube. https://youtu.be/EO2ekPZHUFI
CLINICAL RESEARCH:
ACTIVE GRANTS
Industry:
ACTIVE TRIALS:
USOR 20186 Ph2 Tumor-Agnostic Precision TAPISTRY. Role at MCI. PI.
USOR 19151 Ph1/2 MRTX849 Solids KRAS G12C. Role at MCI. PI
USOR 19144 Biomarker Study to Determine Frequency of DNA-repair Defects in
Men with Metastatic Prostate Cancer. Sponsor: Jansen Research & Development,
LLC. Role at MCI: PI
USOR 18057. Phase 1/2, open-label, first-in-human study of BMS-986249, an anti-T
lymphocyte-associated protein 4 (CTLA-4) ProbodyTM monoclonal antibody (mAb) of
ipilimumab, alone and in combination with nivolumab (anti-programmed cell death 1
[PD-1]), in participants with advanced solid tumors. Funding Agency: US Oncology.
Role: PI at MCI.
Federal:
A31102. Standard-Dose Combination Chemotherapy or High-Dose Combination
Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or
Refractory Germ Cell Tumors. Role at MCI. PI
PIPELINE:
Concept Development/IIT:
2018-BAS-001 Phase I/II Study of the indenoisoquinoline TOP1 inhibitor LMP400
(indotecan) with olaparib in patients with homologous recombination deficient advanced
solid tumors.
2021-BAS-001 Phase 1 Study of Rosiglitazone and Carboplatin in Patients with
Advanced Solid Tumors.
2022-BAS-001 Phase 1 study of Tivozanib with Belzutifan in patients with advanced
Renal Cell Carcinoma.
2022-RETRO-BAS-001: Minorities Participation in Phase I Clinical Trials, a community
center experience.
2022-RETRO-BAS-002: Clinical Outcomes of Treatment Sequencing in AR-V7
Negative Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
PREVIOUS GRANTS
Federal: 184-313
RTOG 0924 Androgen deprivation therapy and high dose radiotherapy with or without
whole-pelvic radiotherapy in unfavorable intermediate or favorable high-risk prostate
cancer: a phase III randomized trial.
Funding Agency: NCI
Role: PI at CCF site
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
(ALCHEMIST).
Funding Agency: NCI
Role: PI at CCF site
A081105 Randomized double blind placebo controlled study of erlotinib or placebo in
patients with completely resected epidermal growth factor receptor (EGFR) mutant non-
small cell lung cancer (NSCLC).
Funding Agency: NCI
Role: PI at CCF site
EA5142 A Randomized Phase III Study of Nivolumab After Surgical Resection and
Adjuvant Chemotherapy in Non-Small Cell Lung Cancers.
Funding Agency: NCI
Role: PI at CCF site
DFCI1Y17 “NCT02888743 / 10021” - Durvalumab and Tremelilumab with or without
High or Low-Dose Radiation Therapy in Treating Patients with Metastatic Colorectal or
Non-Small Cell Lung Cancer.
Funding Agency: NCI
Role: PI at CCF site
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy
Response in Patients with Bladder Cancer.
Funding Agency: NCI
Role: PI at CCF site
ECOG 1505, a phase III randomized trial of adjuvant chemotherapy with or without
bevacizumab for patients with completely resected stages IB (≥4 cm) - IIIA Non-Small
Cell Lung Cancer (NSCLC).
Funding Agency: NCI
Role: PI at CCF site.
CTSU E 5508, a randomized phase III study of maintenance therapy with bevacizumab,
pemetrexed, or a combination of bevacizumab and pemetrexed following carboplatin,
paclitaxel and bevacizumab for advanced non-squamous NSCLC.
Funding Agency: NCI.
Role: PI at CCF site.
ECOG 1305, a phase III randomized trial of chemotherapy with or without bevacizumab
in patients with recurrent or metastatic head and neck cancer. Funding Agency: NCI.
Role: PI at CCF site.
CALGB 90601, a randomized double-blinded phase III study comparing gemcitabine,
cisplatin and bevacizumab to gemcitabine, cisplatin and placebo in patients with
advanced transitional cell carcinoma.
Funding Agency: NCI.
Role: PI at CCF site.
CALGB 90802, a randomized phase III trial comparing everolimus versus everolimus
plus bevacizumab for advanced renal cell carcinoma progressing after treatment with
tyrosine kinase inhibitors.
Funding Agency: NCI.
Role: PI at CCF site.
SWOG S0931, EVEREST: EVErolimus for renal cell carcinoma ensuing surgical
therapy, a phase III study.
Funding Agency: NCI.
Role: PI at CCF site.
SWOG 1404 a Phase III randomized trial comparing Physician/Patient of Choice of
Either High Dose Interferon or Ipililumab to MK-3475 (Pembrolizumab) in patients with
high risk resected melanoma.
Industry:
XL184-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib
in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in
Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk. Sponsor: Exelixis. Role at MCI: Co-PI
PCR3011 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of
Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate
Cancer Who Are Candidates for Radical Prostatectomy. Sponsor: Janssen
Research & Development, LLC. Role at MCI: Co-PI
Actuate 1801 Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-
3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with
Refractory Hematologic Malignancies or Solid Tumors. Funding Agency: Actuate. Role:
PI at MCI.
TP-0903-101 A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety,
Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for
21 Days to Patients with Advanced Solid Tumors. Funding Agency: Tolero. Role: PI at
MCI
USOR18235 A Phase 1 Study to Evaluate the Safety and Tolerability of
Immunotherapy Combinations in Participants with Advanced Malignancies
(AB928CSP0005). Sponsor: Arcus Biosciences, Inc. Role at MCI: PI.
USOR 18214 A Phase 1/2 Study of Galinpepimut-S in Combination with
Pembrolizumab (Mk-3475) in Patients with Selected Advanced Cancers. Sponsor:
Sellas Life Sciences Group. Role at MCI. PI.
TPST1120-001 A Phase 1/1b Open-label, Dose-escalation and Dose-expansion
Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer
Therapies in Subjects With Advanced Solid Tumors. Sponsor: Tempest
Therapeutics. Role at MCI. PI.
QUILT-3.055 A Phase 2b, Single-Arm, Multicohort, Open-Label Study of ALT-803 in
Combination with a PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease
Progression Following an Initial Response to Treatment with PD-1/PD-L1
Checkpoint Inhibitor Therapy. Sponsor Altor Bioscience. Role at MCI: PI.
CheckMate 568 Nivolumab in Combination with Ipilimumab (Part 1); Nivolumab Plus
Ipilimumab in Combination with Chemotherapy (Part 2) as First Line Therapy in Stage
IV Non-Small Cell Lung Cancer.
Sponsor: Bristol Meyers Squibb
Role at CCF: PI
Amount: $183,825.00
STARTRK-2: An open label, multicenter, global phase 2 basket study of entrectinib for
the treatment of patients with locally advanced or metastatic solid tumors that harbor
NTRK1/2/3, ROS1, or AL gene rearrangement.
Sponsor: Ignyta.
Role at CCF: Co-PI
I4E-MC-JXBD, a randomized, double-blind, phase 2 safety study of cetuximab, using
ImClone versus Boehringer Ingelheim, in combination with chemotherapy as first-line in
patients with recurrent or metastatic head and neck cancer.
Sponsor: Lilly
Role at CCF: PI
Amount: $107,015.00
ARQ197-218, a phase II randomized open-label study of erlotinib plus tivantinib (ARQ
197) versus single agent chemotherapy in previously treated KRAS mutation positive
subjects with locally advanced or metastatic NSCLC.
Funding Agency: Arqule.
Role: PI at CCF site.
GO27820, a randomized phase II, multicenter, double-blind, placebo-controlled study
evaluating the efficacy and safety of onartuzumab (MetMAb) in combination with
paclitaxel + cisplatin or carboplatin as first-line treatment for patients with stage IIIB (T4
disease) or IV squamous NSCLC.
Sponsor: F. Hoffman-La Roche Ltd.
Role: PI at CCF site.
Amount: $206,707.50
A randomized double-blind, phase 2 study of Erlotinib in combination with OSI-906 or
Placebo in chemo naïve patients with advanced NSCLC with activating mutations of the
Epidermal Growth Factor Receptor (EGFR) gene.
Sponsor: Astellas.
Role: PI at CCF site.
Amount: $ 118,229.60
A phase II randomized double-blind, placebo controlled, multicenter study of VS-6063 in
subjects with malignant pleural mesothelioma.
Sponsor: Verastem, Inc.
Role: PI at CCF site.
Amount: $92,373.56
An open-label, multi-center, Expanded Treatment Protocol of oral LDK378 in adult
patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity.
Sponsor: Novartis.
Role: PI at CCF site.
Amount: $132,188.00
A multicenter, open-label phase 2 study of the safety and activity of levantinib (E7080) in
subjects with KIF5B-RET-Posiitive Adenocarcinoma of the Lung.
Sponsor: Eisai
Role: PI at CCF site
TIGER-2: A Phase 2, Open-label, multicenter, safety and efficacy study of oral CO-1686
as 2nd Line EGFR-directed TKI in Patients with Mutant EGFR NSCLC.
Sponsor: Clovis Oncology.
Role: PI at CCF site.
Amount: $ 112,120.00
HALO1Y15 A Phase 1b Open-Label Study of PEGylated Recombinant Human
Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected
Hyaluronan-High Solid Tumors.
Funding Agency: Halozyme Therapeutics.
Role: Co-PI at CCF site
IIT:
CASE 1516 - A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction
Non-Ablative Radiation to One of the Target Lesions, in Previously Treated Patients with
Stage IV NSCLC.
Funding Agency: Cleveland Clinic
Role: Co-PI at CCF
BIBLIOGRAPHY
A. Abstracts
1. Brenner N, Bastos B. Perioperative DD-MVAC- a Safe and Efficacious
Treatment for MIBC; Results of a Retrospective Community Center Study
with Clinical Correlated of Toxicity and Response. ASCO 2015. J Clin Oncol
33, 2015 (suppl; abstr e15540)
2. Brenner N, Bastos B. Radiographic patterns of progression in patients with
EGFR mutant NSCLC undergoing EGFR TKI therapy. ASCO 2015. J Clin
Oncol 33, 2015 (suppl; abstr e19108)
3. Manthri S, Bastos, B. A community hospital experience in the use of peri-
operative dose-dense MVAC in patients with muscle-invasive bladder cancer
(MIBC) treated with either robotic cystectomy (RC) or open cystectomy
(OC). ASCO 2014
4. Manthri S, Bastos, B. A community hospital experience on the outcome of
patients with different genetic variant epidermal growth factor receptor
(EGFR) mutant non-small cell lung cancer (NSCLC). ASCO 2014.
5. Bastos B, Diamond J, Hansen R, Gustafson D, Arnott J, Bray M, Sidor C,
Messersmith W, Shapiro G. An open-label, dose escalation, safety, and
pharmacokinetic study of dc administered orally to patients with advanced
cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 3520)
6. Bastos B, Roman E, Negret L, Takita C, Lobo C, Lopes G, Farfan N, Karr M,
Rocha-Lima C, Raez LE. Consolidation Docetaxel After Concurrent
Chemoradiotherapy with Carboplatin and Irinotecan in Unresectable Stage III
NSCLC. J of Thor Onc Oct 2006, Vol 1(8), 902a.
7. Bastos B, Wangpaijit M, Wu C, Robles C, Savaraj N. Overcoming Cisplatin
and VP- 16 Resistance with mTOR Inhibition in Small Cell Carcinoma
Patients. J of Thor Onc Oct 2006, Vol 1(8), 905a.
8. Lopes G, Bastos B, Ahn E, Quesada J, Allison M, Flores A, Ribeiro A, Levi
J, Macintyre J, Rocha-Lima CM. A Phase II Trial of Capecitabine and
Docetaxel in Patients with Previously Treated Pancreatic Cancer. J Clin Oncol
ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20
Supplement), 2006:14111.
B. Educational Exhibits/Posters
1. Martin Gutierrez, Claire Friedman, Georgina V. Long, Paolo A. Ascierto, Ignacio
Melero,Donald Richards, Bruno Bastos,Victor Moreno, Marc Uemura,Paul
Conkling, Bradley R. Corr,Amy Kim, Li Zhu, Amy Hammell,Deepak Perumal,
Armand Chouzy,Fernando Benavente, Ololade Awosemo, Dung LeAnti–
Cytotoxic T Lymphocyte Antigen-4 (CTLA 4) Probody BMS-986249 ±
Nivolumab (NIVO) in Patients (pts) With Advanced Cancers: Updated Phase 1
Results. ESMO 22. Poster
2. Mark Yarchoan, John Powderly, Bruno Bastos, Thomas Karasic, Oxana Crysler,
Pamela Munster, Meredith McKean, Leisha Emens, Yvonne Saenger, Yasser
Ged, Robert Stagg, Steve Smith, Anne Moon, Peppi Prasit, Thomas Dubensky,
Sam Whiting, Susanna Ulahannan. A Phase 1 Study of TPST-1120 as a Single
Agent and in Combination with Nivolumab in Subjects with Advanced Solid
Tumors (NCT03829436). ASCO 22. Oral Presentation.
3. Thomas W. Flaig, Catherine Tangen, Siamak Daneshmand, Ajjai Shivaram Alva,
M. Scott Lucia, David McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I.
Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared Fowles,
Daniel Gustafson, Melissa Plets, Ian Murchie Thompson, Seth P. Lerner. SWOG
S1314: A randomized phase II study of co-expression extrapolation (COXEN)
with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer
with overall survival follow up. ASCO GU 2022. J Clin Oncol 40, 2022 (suppl 6;
abstr 536).
4. J. Sarantopoulos, A.A. Adjei, M. Beg, J. Melear, J. Thompson, F.Y. Tsai, J.C.
Baranda, B. Bastos et al. A phase I, first-in-human, safety, pharmacokinetic, and
pharmacodynamic study of oral dubermatinib (TP-0903) in patients with
advanced solid tumours. ESMO Virtual Congress 2020. 18 Sep 2020. Session:
Mini Oral – Developmental Therapeutics. Abstract 536MO.
5. Carneiro B, Cavalcante L, Bastos BR et al. Phase I study of 9-ing-41, a small
molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a
single agent and combined with chemotherapy, in patients with refractory tumors.
Developmental Therapeutics – Molecularly targeted Agents and Tumor Biology.
Abstract 3506.ASCO20.
6. Gutierrez M, Long G, Friedman C, Richards D, Corr B, Bastos BR et al. Anti-
CTLA-4 probody BMS-986249 alone or in combination with nivolumab in
patients with advanced cancers: Initial phase I results. Developmental
Therapeutics-Immunotherapy. Abstract 3058. ASCO2020.
7. Daniel Olson, Riyue Bao, Jacob B Alfred, Carrie Strand, Yuanyuan Zha, Timothy
C. Carll, Brian Labadie, Bruno R. Bastos, Marcu O. Butler, Pamela N. Munster,
Gary K. Schawrtz, Jason J. Luke. Correlateds of Overall Survival (OS) in
metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo)
versus chemotherapy (chemo). Journal of Clinical Oncology 37, no. 15_suppl
(May 20, 2019) 9506-9506.
8. Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Shivaram
Alva, Seth P. Lerner, M. Scott Lucia, David James McConkey, Dan Theodorescu,
Amir Goldkorn, Matthew I. Milowsky, Richard Carlton Bangs, Gary R.
MacVicar, Bruno R. Bastos, Daniel Gustafson, Melissa Plets, Ian Murchie
Thompson. SWOG S1314: A randomized phase II study of co-expression
extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-
invasive bladder cancer. J Clin Oncol 37, 2019 (suppl; abstr 4506)
9. Sadler D, Nahleh Z, Stone E, Samuel T, Bastos B et al. starting a cardio-oncology
program: a simple approach for rapid growth. Global Cardio Oncology Summit.
Tampa-FL. February 2019.
10. Sadler D, Nahleh Z, Stone E, Samuel T, Bastos B et al. Advancing the Starting
and Sustaining a Cardio Oncology Program: Practical Model to Succeed Utilizing
Existing Resources at Your Institution. Washington DC. January 2019.
11. Bastos B et al Neoadjuvant chemotherapy with Dose-Dense MVAC
(Methotrexate, Vinblastine, Doxorubicin and Cisplatin) in patients with muscle-
invasive bladder cancer in a community based hospital; a retrospective study.
Florida Bladder Cancer Research Symposium. November 2016. FIRST PRIZE
WINNER.
12. Bastos B Et al. Synergistic Combination of PD-1 and EGFR antibodies: a
proposed phase I clinical trial utilizing nivolumab and cetuximab. 2016
Multidisciplinary Head and Neck Cancer Symposium. Scottsdale, Arizona.
February 2016.
13. Marc A. Shapiro, James Stevenson, Emily Van Wagoner, Katherine Glass, Chad
W Cummings, Nathan A. Pennell, Patrick C. Ma, Vamsidhar Velcheti, Bruno R.
Bastos, Brian James Bolwell, Abdo Haddad. Impact of a Stage IV NSCLC care
pathway on front-line (FL) and maintenance (M) chemotherapy use at the
Cleveland Clinic Taussig. Poster Session. J Clin Oncol 33, 2015 (suppl; abstr
6609).
14. Eberechi Sandra Agwa, Francisco Almeida, Abdo Haddad, Bruno R. Bastos,
Roy Lee, Xuefei Jia, Patrick Ma. Clinical implications of repeat tumor biopsy
(RTB) in patients (pts) with advanced lung cancer (LC); the Cleveland Clinic
(CC) experience. ASCO 2015. Poster Session. J Clin Oncol 33, 2015 (suppl; abstr
8077).
15. Jason John Luke, Jacob B Allred, Laura E. Horvath, Bruno R. Bastos, Charles
Erlichman, Gary K. Schwartz. Randomized phase II study comparing the MET
inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular
melanoma: A091201. ASCO 2015. Poster Session. J Clin Oncol 33, 2015 (suppl;
abstr TPS9087).
16. Gerber D, Bastos B et. al. Randomized Phase 2 Study of Tivantinib (ARQ 197)
Plus Erlotinib vs. Single-agent Chemotherapy in Previously Treated KRAS
Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). 2014 Chicago
Multidisciplinary symposium in Thoracic Oncology November 2014 (Accepted
for poster presentation).
17. Paul J. E. Miller, Mark S. Walker, Kurt W. Tauer, James Atkins, Kulumani M
Sivarajan, Vipul M. Patel, Bruno R. Bastos, Krista Meyer, Joanna Roder, Lisa
Uyeda, Suzanne Salazar, Corey J. Langer, Mark A. Socinski, David R. Spigel,
Lee Steven Schwartzberg. Serum and tumor biomarkers predict outcome in the
elung trial, a multicenter, randomized phase 2b study of standard platinum
doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small
cell lung cancer (NSCLC). Selected as poster presentation for ASCO 2013.
Chicago, IL.
18. L. S. Schwartzberg, K. Tauer, J. Atkins, K. Sivarajan, V. Patel, B. Bastos, C.
Langer, M. A. Socinski, D. R. Spigel. LBA30 - eLung: A Multicenter,
Randomized Phase IIb Trial of “Standard” Platinum Doublets plus Cetuximab
(CET) as First-line Treatment of Recurrent or Advanced Non-Small Cell Lung
Cancer (NSCLC). Proffered Paper. ESMO. 30 September 2012.
19. Bruno R. Bastos, J. Diamond, R. Hansen, D. Gustafson, J. Arnott, M. Bray, C.
Sidor, W. Messersmith, G. Shapiro. An open-label, dose escalation, safety, and
pharmacokinetic study of ENMD-2076 administered orally to patients with
advanced cancer. Poster Discussion Session, Developmental Therapeutics:
Molecular Therapeutics. ASCO 2010. Orlando, FL.
20. Sharma S, Tibes R, Bastos B et al. CBP501, a novel cell cycle dysregulator, in
combination with cisplatin (CDDP) and pemetrexed (PM) – results of two phase
I/II studies. 2009 AACR-NCI-EORTC Molecular Targets and Cancer
Therapeutics Conference. Boston, MA. November 2009.
21. Elgart G, Tzu J, Bastos B. Extramedullary relapse of leukemia cutis limited to the
skin. American Society of Dermato-Pathology - 45th Annual Meeting. San
Francisco, CA. October 2008.
22. Stefanovic A, Bastos B, Ernst S. Gastric Signet-Ring-Cell Carcinoma Presenting
with Leptomeningeal Carcinomatosis - A Case Report. University of Miami
Sylvester Comprehensive Cancer Center, 7th Annual Zubrod Lecture and
Research Poster Competition, Miami, FL, May 2006.
23. Bastos B, Ramos JC, Cabral L, Harrington WJ. Complete Remission of Oral
Plasmablastic Lymphoma with Antiviral Therapy. University of Miami Sylvester
Comprehensive Cancer Center, 4th Annual Zubrod Lecture and Research Poster
Competition, Miami, FL, May 2003.
24. Coutinho A, Bastos B. Lacrimal Gland Metastasis as the Primary Manifestation
of Breast Cancer - A Case Report. Annual Meeting of the Brazilian Society of
Clinical Oncology, Florianopolis, SC, Brazil, November 2001.
C. Publications
1. Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, Carneiro BA, Bastos
BR, Mikrut S, Mikrut W, Giles FJ, Sahebjam S.Malignant glioma subset from actuate
1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with
chemotherapy for refractory malignancies. Neurooncol Adv. 2022 Feb 7;4(1):vdac012.
doi: 10.1093/noajnl/vdac012. eCollection 2022 Jan-Dec.PMID: 35402914.
2. Flaig T, Tangen C, Daneshmand S, Alva A, Lerner S, Lucia MS, McConkey D,
Theodorescu D, Goldkorn A, Milowsky M, Bangs R, MacVica G, Bastos BR, et al. A
randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant
chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021
Feb 10.
3. Bao R, Surriga O, Olson D, Allred J, Strand C, Zha Y, Call T, Labadie B, Bastos BR et
al. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a
therapeutic target. Melanoma Res. 2021 Feb; 3.
4. Sadler D, Chaulagain C, Alvarado B, Cubeddu R, Stone E, Sauel T, Bastos B et al.
Practical and cost-effective model to build and sustain a cardio-oncology program.
Cardiooncology. 2020 Jul 16.
5. Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos
BR et al. Randomized phase II trial and tumor mutation spectrum analysis from
cabozantinib versus chemotherapy in metastatic uveal melanoma (alliance A091201).
Clin Cancer Res. 2020 Feb 15.
6. Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP,
Lilenbaun RC, Bastos BR et al. Randomized phase 2 study of tivantinib plus erlotinib
versus single-agent chemotherapy in previously treated KRAS mutant non-small cell lung
cancer. Lung Cancer. 2018. Mar.
7. Schroeder JR, Gleason JB, Bastos B, et al. Where is the Air? J Clinic Diagn Res. 2017
Feb.
8. Bastos BR, Lilenbaum RC. Combining EGF receptor inhibitors with chemotherapy or
chemoradiotherapy in patients with non-small-cell lung cancer. Therapy. January 2011.
9. Pinto D, et al, Bastos B. Reversible posterior leukoencephalopathy syndrome secondary
to Bevacizumab: a case report. J Hematol Oncol Pharm. 2011; 1(2):10-14.
10. Diamond JR, Bastos BR et al. Phase I Safety, Pharmacokinetic and Pharmacodynamic
Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with
Advanced Solid Tumors. Clin Cancer Res February 15, 2011.
11. Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS,
Vogelzang NJ, Bastos BR et al. Phase I Studies of CBP501, a G2 Checkpoint Abrogator,
as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid
Tumors. Clin Cancer Res. 2011 Jan 10.
12. Bastos BR et al. Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and
Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-Small
Cell Lung Cancer. J Thoracic Oncol. 2010 Apr.